Thanks to travelers, Zika could be a $1B+ vaccine opportunity: Reuters : fiercepharma

as mentioned in fiercepharma

Thanks to travelers, Zika could be a $1B+ vaccine opportunity: Reuters

Thanks to travelers, Zika could be a $1B+ vaccine opportunity: Reuters

Though still years out, an effective Zika vaccine could beat a path to blockbuster sales, thanks to demand from travelers to endemic areas--which include some common tourist destinations.That's a key difference from the limited market prospects in other mosquito-borne diseases.That blockbuster potential, plus an urgent medical need, has prompted a burst of R&D in the field, Reuters reports.


additionally salon

Zika vaccine trials have graduated from monkeys to humans, but still far off

Zika vaccine trials have graduated from monkeys to humans, but still far off

This article was originally published on The Conversation.Recent news articles have highlighted positive findings in experimental Zika virus pre-clinical vaccine studies in monkeys and described the start of two Zika virus vaccine trials in humans.These stories have spurred hopes that a Zika virus vaccine will be available to prevent this infection, and its secondary effects, such as abnormal fetal development.


additionally bangkokpost

Zika vaccine race spurred by huge profit potential

Zika vaccine race spurred by huge profit potential

The race to find protection against the Zika virus is fuelled by something often missing from tropical disease research: the potential for big profit.The prospect of a blockbuster vaccine against a mosquito-borne virus has accelerated the pace of development and attracted the interest of big drugmakers, including Sanofi SA, GlaxoSmithKline Plc and Takeda Pharmaceuticals.Although Zika infections are mild or asymptomatic in most people, demand for a vaccine is expected to be strong because it can cause devastating birth defects, pharmaceutical executives and disease experts said.